Research Topics
Species | Robin E PearceSummaryAffiliation: Children's Mercy Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoformsR E Pearce
Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospital, Kansas City, Missouri 64108, USA
Drug Metab Dispos 29:1548-54. 2001..g., ontogeny of drug-metabolizing enzymes, inhibition, and induction) should be clinically unimportant due to the apparent lack of dependence on cytochromes P450 for elimination...- Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolitesRobin E Pearce
Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
Drug Metab Dispos 30:1170-9. 2002..These results suggest that CYP2B6 and CYP3A4 are largely responsible for the formation of 3-hyrdoxycarbamazepine, whereas multiple P450s (CYP1A2, 2A6, 2B6, 2E1, and 3A4) contributed to 2-hydroxycarbamazepine formation... 
Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepineRobin E Pearce
Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
Drug Metab Dispos 36:1637-49. 2008....- Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbeneRobin E Pearce
Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, Missouri 64108, USA
Drug Metab Dispos 33:1819-26. 2005.... - Variability of CYP2J2 expression in human fetal tissuesAndrea Gaedigk
Children s Mercy Hospital, Division of Clinical Pharmacology, 2401 Gillham Rd, Kansas City, MO 64108, USA
J Pharmacol Exp Ther 319:523-32. 2006..Due to premature termination codons, none encodes functional protein. The mechanisms leading to variable amounts of immunoreactive protein and distinct pre- and postnatal CYP2J2 protein patterns warrant further investigation... 
Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotypeJ Steven Leeder
Section of Developmental Pharmacology and Experimental Therapeutics, Department of Pediatrics, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
J Clin Pharmacol 48:1041-51. 2008..Although further development is required, these studies suggest that the [(13)C]-DM breath test offers promise as a rapid, minimally invasive phenotyping assay for CYP2D6 activity...- Variability of CYP3A7 expression in human fetal liverJ Steven Leeder
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
J Pharmacol Exp Ther 314:626-35. 2005..2-fold (8.07 +/- 2.87, range 2.41 to 14.9 nmol/min/mg). Observed variability in CYP3A7 activity was not related to CYP3A7*2, and alternative regulatory mechanisms require further investigation... - Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infantsMichael J Blake
Department of Pediatrics, University of Missouri Kansas City, School of Medicine and the Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
Pediatr Res 60:717-23. 2006..Dietary modification of CYP activity may modulate drug biotransformation and thus alter systemic exposure to xenobiotics from a very early age... - Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populationsAndrea Gaedigk
Division of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
Eur J Clin Pharmacol 66:859-64. 2010..We aimed to resolve the CYP2D6 31 no-calls, determine the allele haplotype, and corroborate that CYP2D6 31 is associated with a poor metabolizer phenotype... - Ontogeny of dextromethorphan O- and N-demethylation in the first year of lifeM J Blake
Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
Clin Pharmacol Ther 81:510-6. 2007..In contrast, DM N-demethylation developed significantly more slowly over the first year of life. Genotype and the temporal acquisition of drug biotransformation are critical determinants of a drug response in infants... - Biotransformation of fluticasone: in vitro characterizationRobin E Pearce
Division of Pediatric Clinical Pharmacology and Medical Toxicology, Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
Drug Metab Dispos 34:1035-40. 2006..These results suggest that at pharmacologically relevant concentrations, biotransformation of FTP to M1 is mediated predominantly by CYP3A enzymes in the liver... - Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotypeA Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
Clin Pharmacol Ther 81:817-20. 2007..The rationale for this study was to resolve the discordance and to describe the novel non-functional allelic variant of CYP2D6 and its frequency in populations of different ethnic backgrounds... - The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotypeA Gaedigk
Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
Clin Pharmacol Ther 83:234-42. 2008..The AS tool warrants further prospective evaluation for CYP2D6 substrates and in additional ethnic populations... - Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African AmericansA Gaedigk
Division of Clinical Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, MO 64108, USA
Pharmacogenomics J 5:173-82. 2005..CYP2D6(*)45 and (*)46 have a combined frequency of 4% and can be identified by a common SNP. Carriers are predicted to exhibit an extensive or intermediate CYP2D6 phenotype... - Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquineKenda A Marcucci
Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Toxicology, Children's Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA
Drug Metab Dispos 30:595-601. 2002..1. These data indicate that CYP2D6.17 exhibits reduced metabolic activity toward all three commonly used CYP2D6 substrates, although specific effects on substrate affinity and turnover demonstrate some substrate dependence... - CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profilePing Kang
Department of Cellular and Molecular Pharmacology, Liver Center, University of California, San Francisco, 600 16th Street N572F, San Francisco, CA 94158 2280, USA
Drug Metab Dispos 36:490-9. 2008....